Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Authors
Keywords
-
Journal
DIABETOLOGIA
Volume 63, Issue 4, Pages 698-710
Publisher
Springer Science and Business Media LLC
Online
2020-01-27
DOI
10.1007/s00125-019-05080-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes
- (2018) T.S. Bailey et al. DIABETES & METABOLISM
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
- (2018) Julio Rosenstock et al. DIABETES CARE
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes
- (2017) Carol Wysham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes
- (2016) Lisa Elliott et al. Diabetes Therapy
- Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes
- (2016) Lisa Elliott et al. Diabetes Therapy
- Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
- (2015) R. Ritzel et al. DIABETES OBESITY & METABOLISM
- One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
- (2015) M. C. Riddle et al. DIABETES OBESITY & METABOLISM
- Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extensi
- (2015) H. Yki-Järvinen et al. DIABETES OBESITY & METABOLISM
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
- (2015) G. B. Bolli et al. DIABETES OBESITY & METABOLISM
- Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- (2015) Tim Heise et al. Expert Opinion on Drug Metabolism & Toxicology
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
- (2014) Matthew C. Riddle et al. DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
- (2014) Hannele Yki-Järvinen et al. DIABETES CARE
- New Insulin Glargine 300 units{middle dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 units{middle dot}mL-1
- (2014) R. H. A. Becker et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
- (2014) Jiten Vora et al. Diabetes Therapy
- A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec
- (2013) Stefan Korsatko et al. CLINICAL DRUG INVESTIGATION
- Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes
- (2013) Stephen C.L. Gough et al. DIABETES CARE
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) E. R. Seaquist et al. DIABETES CARE
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- How hypoglycaemia can affect the life of a person with diabetes
- (2007) Brian M. Frier DIABETES-METABOLISM RESEARCH AND REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now